ArticleJournal of family medicine and primary care2026
A comparative analysis of vortioxetine vs. escitalopram on the clinical profile of patients with major depressive disorder.
Article in Journal of family medicine and primary care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Major depressive disorder (MDD) remains a leading cause of disability worldwide, necessitating effective pharmacological treatments. Selective serotonin reuptake inhibitors (SSRIs) like escitalopram and newer antidepressants like vortioxetine are commonly prescribed for managing MDD. Although both medications are widely used, comparative data on their clinical and cognitive efficacy remains limited. Objective: This study aims to compare the clinical effectiveness of escitalopram and vortioxetine in alleviating depressive symptoms, with a particular focus on symptom reduction over a 4-week treatment period. Methods: This was a prospective, randomized, open-label study conducted at a tertiary care center from October 2023 to October 2024. A total of 100 patients diagnosed with MDD were randomly assigned to receive either escitalopram (10 mg/day, n = 50) or vortioxetine (10 mg/day, n = 50). Symptom severity was assessed using the Hamilton Depression Rating Scale (HAM-D) at baseline, 2 weeks, and 4 weeks. Statistical significance was evaluated using appropriate tests. Results: Both Escitalopram and Vortioxetine produced significant reductions in HAM-D scores over the 4-week period. By Week 4, escitalopram demonstrated a statistically significant superior effect in symptom reduction compared to vortioxetine (mean HAM-D score: 14.22 vs. 16.32, Conclusion: Both escitalopram and vortioxetine effectively reduce depressive symptoms in patients with MDD, with escitalopram showing a more rapid onset of symptom relief. Further long-term studies are warranted to assess the sustained efficacy and cognitive benefits of both medications in diverse patient populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.